Consistency of Efficacy, Patient Acceptability, and Nasal Tolerability of Fentanyl Pectin Nasal Spray Compared with Immediate-Release Morphine Sulfate in Breakthrough Cancer Pain  Andrew Davies, MBBS, MSc, MD, FRCP, Thomas Sitte, Frank Elsner, MD, Carlo Reale, MD, Jose Espinosa, MD, David Brooks, MD, Marie Fallon, MB, ChB, MD, FRCP  Journal of Pain and Symptom Management  Volume 41, Issue 2, Pages 358-366 (February 2011) DOI: 10.1016/j.jpainsymman.2010.11.004 Copyright © 2011 U.S. Cancer Pain Relief Committee Terms and Conditions

Fig. 1 Overall patient acceptability assessments (ease of use and convenience) of a nasal spray after last treated episode (n=79). Missing values: 12.7%. Journal of Pain and Symptom Management 2011 41, 358-366DOI: (10.1016/j.jpainsymman.2010.11.004) Copyright © 2011 U.S. Cancer Pain Relief Committee Terms and Conditions

Fig. 2 Patient nasal symptom scores at 60 minutes after dose. Patients completed a nasal symptom score for 10 symptoms where 0=absent, 1=mild, 2=moderate, and 3=severe. The average nasal symptom score was averaged over all episodes treated during the double-blind, double-dummy treatment phase. Journal of Pain and Symptom Management 2011 41, 358-366DOI: (10.1016/j.jpainsymman.2010.11.004) Copyright © 2011 U.S. Cancer Pain Relief Committee Terms and Conditions